Ko, Seung-Hyun

Epidemic obesity and type 2 diabetes in Asia

Yoon, K.-H., Lee, J.-H., Kim, J.-W., Cho, J. H., Choi, Y.-H., Ko, S.-H., Zimmet, P., & Son, H.-Y. (2006) · The Lancet

Diabetes, Cardiovascular Risks, and LipoproteinsObesity, Physical Activity, Diet

Cited by 1,580

Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes

Yun, J.-S., & Ko, S.-H. (2021) · Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 292

Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice

Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 218

Clinical guidelines for the management of adrenal incidentaloma

Lee, J.-M., Kim, M. K., Ko, S.-H., Koh, J.-M., Kim, B.-Y., Kim, S. W., Kim, S.-K., Kim, H. J., Ryu, O.-H., Park, J., et al. (2017) · Endocrinology and Metabolism

Adrenal and Paraganglionic TumorsHormonal Regulation and Hypertension

Cited by 147

Efficacy of Personalized Diabetes Self-care Using an Electronic Medical Record–Integrated Mobile App in Patients With Type 2 Diabetes: 6-Month Randomized Controlled Trial

Lee, E. Y., Cha, S.-A., Yun, J.-S., Lim, S.-Y., Lee, J.-H., Ahn, Y.-B., Yoon, K.-H., Hyun, M. K., & Ko, S.-H. (2022) · Journal of Medical Internet Research

Mobile Health and mHealth ApplicationsDiabetes Management and Education

Cited by 83

Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013)

on Behalf of the Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association, Jung, C. H., Chung, J. O., Han, K., Ko, S.-H., Ko, K. S., & Park, J.-Y. (2017) · Cardiovascular Diabetology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 74

Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea

Chang, S. A., Kim, H. S., Yoon, K. H., Ko, S. H., Kwon, H. S., Kim, S. R., Lee, W. C., Yoo, S. J., Son, H. S., Cha, B. Y., et al. (2004) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 66

Exendin‐4 inhibits iNOS expression at the protein level in LPS‐stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway

Chang, S., Kim, D., Ryu, G. R., Ko, S., Jeong, I., Ahn, Y., Jo, Y., & Kim, M. (2013) · Journal of Cellular Biochemistry

Diabetes Treatment and ManagementNeuropeptides and Animal Physiology

Cited by 44

Exendin-4 inhibits interleukin-1β-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F β-cells

Kang, J.-H., Chang, S.-Y., Jang, H.-J., Kim, D.-B., Ryu, G. R., Ko, S. H., Jeong, I.-K., Jo, Y.-H., & Kim, M.-J. (2009) · Journal of Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 30

Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα

Wang, N., Ko, S.-H., Chai, W., Li, G., Barrett, E. J., Tao, L., Cao, W., & Liu, Z. (2011) · American Journal of Physiology-Endocrinology and Metabolism

Sirtuins and Resveratrol in MedicineNitric Oxide and Endothelin Effects

Cited by 28

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension

Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 10